Sort by:
Need a comprehensive medical report on "Boehringer Ingelheim"?
Analyze the latest clinical research and treatment options
Summarize scientific findings from medical journals
Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02251158
Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 97
- Registration Number
- NCT02251197
Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: BIIL 284 BS low doseDrug: PlaceboDrug: BIIL 284 BS medium doseDrug: BIIL 284 BS high dose
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 404
- Registration Number
- NCT02251210
Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects
Phase 1
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2014-09-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 208
- Registration Number
- NCT02251223
Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 657
- Registration Number
- NCT02248220
Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 198
- Registration Number
- NCT02248116
Antihypertensive Medications and the Risk of Sepsis
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Other angiotensin-receptor blockers (ARBs)Drug: Angiotensin-converting enzyme inhibitors (ACEIs)Drug: Other major antihypertensive medication classes
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1129062
- Registration Number
- NCT02248896
Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4255
- Registration Number
- NCT02248129
Pharmacokinetics and Pharmacodynamics of BIWH 3 in Healthy Duffy Positive vs. Duffy Negative Male Volunteers
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT02249117
Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 442
- Registration Number
- NCT02248181